UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41097 Cardio Diagnostics Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 87-0925574 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File Number: 001-41612 ASSET ENTITIES INC. (Exact name of registrant as specified in its charter) Nevada 88-1293236 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 1847 Holdings LLC | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | Delaware | 001-41368 | 38-3922937 | | (State or other jurisdiction | (Commission File Number) | (IRS Employer | | of incorporation) | | Identification No.) | | 260 Madison Avenue, ...

Exhibit 99.1 Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 3 ...

Financial Results and Updates - TuHURA Biosciences reported financial results for Q1 2025, with a focus on corporate updates[7]. - TuHURA's financial condition and operational results are detailed in the press release dated May 15, 2025[7]. - The company has not undertaken any obligation to update forward-looking statements unless required by securities laws[14]. Acquisition and Merger - The company is in the process of acquiring Kineta, Inc., with a registration statement filed on February 7, 2025[8]. - The merger with Kineta is expected to enhance TuHURA's capabilities in tumor microenvironment modulators[13]. - TuHURA is actively seeking additional capital to support the Kineta merger and its ongoing development programs[13]. - The company emphasizes the importance of reading the Joint Proxy Statement/Prospectus for detailed information regarding the merger[9]. Product Development - TuHURA's product candidate IFx-Hu2.0 is anticipated to enter Phase 3 trials, indicating progress in its development pipeline[13]. - The anticipated regulatory pathway and timing for TuHURA's development programs are outlined as part of their forward-looking statements[13]. Stock Information - TuHURA's stock is traded on The Nasdaq Capital Market under the symbol HURA[5].

[Form 8-K: Current Report](index=1&type=section&id=Form%208-K) This Form 8-K details company and filing information, recent financial results, a proposed merger, cautionary statements, and relevant exhibits [Company and Filing Details](index=1&type=section&id=Company%20and%20Filing%20Details) This Form 8-K was filed by TuHURA Biosciences, Inc. on May 15, 2025, with its common stock registered on The Nasdaq Capital Market under the symbol HURA - Filing entity: **TuHURA BIOSCIENCES, INC.**, a Nevada corporation[2](index=2&type=chunk) - Report date: **May 15, 2025**[2](index=2&type=chunk) Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :--- | :--- | :--- | | Common Stock, $0.001 par value per share | HURA | The Nasdaq Capital Market | [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) On May 15, 2025, TuHURA Biosciences issued a press release (Exhibit 99.1) announcing its financial results for the three months ended March 31, 2025, and providing a corporate update, with the information considered furnished, not filed - A press release was issued on **May 15, 2025**, detailing financial results for the quarter ended **March 31, 2025**[7](index=7&type=chunk) - Exhibit 99.1, the press release, includes a corporate update[7](index=7&type=chunk) - Information in this report and exhibit is furnished, not filed, under the Securities Exchange Act of 1934, unless explicitly referenced in future filings[7](index=7&type=chunk) [Proposed Merger with Kineta, Inc.](index=3&type=section&id=Proposed%20Merger%20with%20Kineta%2C%20Inc.) This section details the proposed merger with Kineta, Inc., referencing the Form S-4 registration statement filed with the SEC, clarifying that this 8-K is not a solicitation and identifying participants [Important Additional Information](index=3&type=section&id=Important%20Additional%20Information) TuHURA filed a Form S-4 registration statement on February 7, 2025, containing a preliminary joint proxy statement and prospectus regarding the proposed merger with Kineta, which will be available on the SEC and TuHURA websites - TuHURA filed a Form S-4 registration statement with the SEC on **February 7, 2025**, regarding the proposed merger with Kineta, Inc[8](index=8&type=chunk) - Investors are urged to review the Joint Proxy Statement/Prospectus for critical merger information[8](index=8&type=chunk) - Finalized documents will be mailed to stockholders and accessible on the SEC's website (www.sec.gov) and TuHURA's website (www.tuhurabio.com)[9](index=9&type=chunk) [No Offer or Solicitation](index=3&type=section&id=No%20Offer%20or%20Solicitation) This Form 8-K is explicitly not a proxy statement, an offer to sell, or a solicitation of an offer to buy any securities in relation to the merger, with any securities offering to be conducted via a prospectus - This Form 8-K is not a proxy statement or a solicitation for the merger[10](index=10&type=chunk) - It does not constitute an offer to sell or a solicitation to buy securities of TuHURA or Kineta[10](index=10&type=chunk) [Participants in the Solicitation](index=3&type=section&id=Participants%20in%20the%20Solicitation) The directors and executive officers of both TuHURA and Kineta may be considered participants in the solicitation of proxies for the merger, with details regarding their interests disclosed in SEC filings and the Joint Proxy Statement/Prospectus - Directors and officers of TuHURA and Kineta may be considered participants in the merger's proxy solicitation[11](index=11&type=chunk) - Information on TuHURA's directors and officers is available in its Form 10-K filed on **March 31, 2025**[11](index=11&type=chunk) - Further details on participant interests will be provided in the Joint Proxy Statement/Prospectus[11](index=11&type=chunk)[12](index=12&type=chunk) [Cautionary Statement Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Statement%20Regarding%20Forward-Looking%20Statements) This report contains forward-looking statements concerning TuHURA's product candidates, development programs, the proposed merger with Kineta, and capital requirements, which are based on current expectations and not guarantees of future performance, with no obligation to update them - Forward-looking statements cover TuHURA's **IFx-Hu2.0** product candidate, tumor microenvironment modulators program, and the potential acquisition of Kineta Inc[13](index=13&type=chunk) - Statements also address capital resources, additional capital needs (including for the Kineta merger), and regulatory pathways[13](index=13&type=chunk) - The company disclaims any obligation to publicly update or revise forward-looking statements unless legally mandated[14](index=14&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=4&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits filed with the Form 8-K, primarily the press release from May 15, 2025, containing financial results and a corporate update Exhibits | Exhibit No. | Document Description | | :--- | :--- | | 99.1 | Press Release, dated May 15, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=7&type=section&id=Signatures) The report was officially signed on May 15, 2025, by Dan Dearborn, the Chief Financial Officer of TuHURA Biosciences, Inc - The report is signed by **Dan Dearborn**, Chief Financial Officer[21](index=21&type=chunk) - Signature date: **May 15, 2025**[21](index=21&type=chunk)

Financial Position - As of March 31, 2025, the company had approximately $70 in its operating bank account and a working capital deficit of approximately $3.4 million[192]. - The company has a total of $1,474,000 outstanding under Working Capital Loans as of March 31, 2025[193]. - The company has no off-balance sheet arrangements as of March 31, 2025[202]. Net Loss - For the three months ended March 31, 2025, the company reported a net loss of approximately $692,000, which included approximately $491,000 in non-operating loss from the change in fair value of derivative warrant liabilities[189]. - For the three months ended March 31, 2024, the company had a net loss of approximately $947,000, with general and administrative expenses amounting to approximately $1.8 million[190]. Business Operations - The company has not engaged in any operations or generated any revenues to date, with only organizational activities conducted since inception[188]. - The company intends to complete an initial business combination by June 25, 2025, but there is substantial doubt about its ability to continue as a going concern if this is not achieved[201]. - The company expects to incur significant costs in pursuing its initial business combination, which may affect its liquidity[187]. - The company has incurred increased expenses due to being a public company, including legal and compliance costs[188]. Debt Obligations - The company issued an unsecured promissory note totaling up to $10,947,000 to the Sponsor, with $10,947,000 outstanding as of March 31, 2025[196].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to _________ 001-39732 Commission File Number Alset Inc. (Exact name of registrant as specified in its charter) TEXAS 83-1079861 State or other jurisdiction of ...

Revenue Performance - Revenue for Q4 2024 was $73.3 million, a 1.1% increase from $72.5 million in Q4 2023, driven by a $1.1 million growth in IoT Connectivity revenue[5] - Full year revenue totaled $286.1 million, up $9.5 million or 3.4% from $276.6 million in 2023, with IoT Connectivity revenue increasing by $24.5 million to $226.9 million[9] - KORE's total revenue for the year ended December 31, 2024, was $146,076,000, down from $167,042,000 in 2023[38] - The company expects revenue for 2025 to be in the range of $288 million to $298 million[14] Financial Loss and Improvement - Net loss for Q4 2024 improved to $25.4 million, a reduction of 24.6% compared to $33.7 million in Q4 2023[9] - KORE Group Holdings reported a net loss of $25,448,000 for Q4 2024, an improvement from a net loss of $33,692,000 in Q4 2023[38] - The company incurred a goodwill impairment loss of $65,861,000 for the year ended December 31, 2024[38] Cash Flow and EBITDA - Adjusted EBITDA for Q4 2024 was $14.0 million, a slight increase of 1.1% from $13.8 million in Q4 2023[9] - Adjusted EBITDA for Q4 2024 was $13,976,000, slightly up from $13,824,000 in Q4 2023[38] - Free Cash Flow for Q4 2024 was $1.6 million, a significant improvement from a negative $15.5 million in Q4 2023[9] - Free cash flow for Q4 2024 was $1,562,000, compared to a negative free cash flow of $15,546,000 in Q4 2023[39] - Total cash provided by operating activities for Q4 2024 was $2,840,000, a significant recovery from a cash used of $10,912,000 in Q4 2023[39] Operational Metrics - The total number of IoT Connections increased by 1.2 million to 19.7 million by the end of 2024[4] - The Dollar-Based Net Expansion Rate (DBNER) for the twelve months ending December 31, 2024, was 95%, down from 96% in the previous year[11] - KORE's average revenue per user (ARPU) is a key metric for assessing revenue generation per connection, calculated on a quarterly basis[33][34] Restructuring and Future Outlook - KORE completed its restructuring plan, resulting in over $20 million in annual run-rate savings[5] - Notable new business wins in Q4 included closed-won Total Contract Value (TCV) of $29.3 million, with $9.4 million related to Connectivity[13] - The company anticipates future revenue growth and operational efficiency improvements as part of its restructuring plan[35] - KORE's integration-related restructuring costs for the year were $19,159,000, compared to $16,532,000 in 2023[38] - The company reported a change in fair value of warrant liability of $2,309,000 for Q4 2024[38]

[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Unaudited Q1 2025 financials indicate a net loss, reduced cash, and a shareholders' deficit, raising going concern doubts [Condensed Consolidated Balance Sheets (Unaudited)](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets%20(Unaudited)) The March 31, 2025 balance sheet reflects decreased assets and cash, increased liabilities, and a shift to a shareholders' deficit Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $122 | $1,173 | | Total Current Assets | $2,120 | $3,776 | | **Total Assets** | **$2,195** | **$3,883** | | **Liabilities & Equity** | | | | Accounts Payable | $2,438 | $1,274 | | Notes Payable | $261 | $0 | | Total Current Liabilities | $4,744 | $3,295 | | Total Liabilities | $4,784 | $3,729 | | Total Shareholders' (Deficit) Equity | ($2,589) | $154 | | **Total Liabilities & Shareholders' (Deficit) Equity** | **$2,195** | **$3,883** | [Condensed Consolidated Statements of Operations (Unaudited)](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20(Unaudited)) Q1 2025 operations show a reduced net loss of $2.9 million, driven by lower research and development and general and administrative expenses Condensed Consolidated Statements of Operations (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Research and development | $1,977 | $2,288 | | General and administrative | $1,264 | $1,407 | | **Total operating expenses** | **$3,241** | **$3,695** | | Net operating loss | ($3,241) | ($3,695) | | Change in fair value of warrant liability | $394 | $538 | | **Net loss** | **($2,852)** | **($3,157)** | | Net loss per share, basic and diluted | ($0.40) | ($4.88) | [Condensed Consolidated Statements of Cash Flows (Unaudited)](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20(Unaudited)) Q1 2025 cash flows reflect $1.3 million used in operations and a $1.1 million net decrease in cash, ending with $0.1 million Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,313) | ($1,038) | | Net cash provided by financing activities | $262 | $174 | | **Net decrease in cash** | **($1,051)** | **($864)** | | Cash, beginning of period | $1,173 | $1,052 | | **Cash, end of period** | **$122** | **$188** | [Notes to the Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's business, accounting policies, and significant going concern doubt due to insufficient cash, alongside new debt financing - The company is a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing its proprietary DNAbilize® technology platform[20](index=20&type=chunk) - There is substantial doubt about the Company's ability to continue as a going concern, as **cash of $0.1 million** at March 31, 2025, plus April 2025 note proceeds, will not fund operations for the next 12 months[25](index=25&type=chunk) - In March 2025, the Company issued two promissory notes totaling **$261.55 thousand** principal, receiving **$227 thousand** net proceeds, with a **12%** one-time interest charge[33](index=33&type=chunk)[34](index=34&type=chunk) - The fair value of the warrant liability decreased from **$0.4 million** at year-end 2024 to **$40 thousand** at March 31, 2025, resulting in a non-cash gain of **$0.4 million**[40](index=40&type=chunk)[42](index=42&type=chunk) - Subsequent to quarter-end, in April 2025, the company issued another promissory note for a principal of **$161 thousand** at a purchase price of **$140 thousand**[60](index=60&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage pipeline, reduced Q1 2025 net loss, and critical liquidity issues raising going concern doubts [Overview](index=24&type=section&id=Overview) The company is a clinical-stage RNAi drug developer with a pipeline including oncology and obesity candidates, highlighting progress in AML trials - The lead drug candidate, prexigebersen, is in a Phase 2 clinical trial for AML, with interim data showing a **75% remission rate** in 20 evaluable newly diagnosed patients[63](index=63&type=chunk)[69](index=69&type=chunk) - The Phase 1 clinical trial for BP1002 in refractory/relapsed lymphoma and CLL was discontinued to focus on the obesity program due to enrollment challenges[70](index=70&type=chunk) - The company is exploring BP1001-A for obesity treatment, with preclinical data confirming increased insulin sensitivity and plans for an IND filing in 2025[76](index=76&type=chunk)[77](index=77&type=chunk) - On February 19, 2025, the company's stock was delisted from Nasdaq and began trading on the OTCQB Venture Market under the symbol 'BPTH'[85](index=85&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q1 2025 results show no revenue, with reduced R&D and G&A expenses leading to an improved net loss compared to Q1 2024 Comparison of Operating Results (in thousands) | Expense Category | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Research and development expense | $1,977 | $2,288 | | General and administrative expense | $1,264 | $1,407 | | **Net Loss** | **$2,852** | **$3,157** | - The decrease in R&D expense was primarily due to decreased clinical trial expenses for BP1001 and BP1002 related to patient enrollment timing[95](index=95&type=chunk) [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces critical liquidity issues with only **$0.1 million** cash, insufficient for 12 months, relying on equity and debt financing - The company had a cash balance of **$0.1 million** as of March 31, 2025, insufficient to meet obligations and fund liquidity for the next 12 months[100](index=100&type=chunk) - Net cash used in operating activities was **$1.3 million** for the three months ended March 31, 2025[101](index=101&type=chunk) - Net cash provided by financing activities was **$0.3 million** for Q1 2025, sourced from warrant exercises and March 2025 Promissory Notes[103](index=103&type=chunk) - The company has engaged in multiple financing activities, including registered direct offerings, private placements, ATM offerings, and promissory notes in March and April 2025 to raise capital[105](index=105&type=chunk)[108](index=108&type=chunk)[111](index=111&type=chunk)[112](index=112&type=chunk)[116](index=116&type=chunk)[119](index=119&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is not applicable to the company for the reporting period - Not applicable[125](index=125&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal controls - Management concluded that the company's disclosure controls and procedures were effective as of the end of the reporting period[127](index=127&type=chunk) - There were no material changes in internal control over financial reporting during the quarter[130](index=130&type=chunk) [PART II - OTHER INFORMATION](index=44&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no legal proceedings - None[132](index=132&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported from the prior Annual Report on Form 10-K - There were no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024[133](index=133&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities or use of proceeds for the period - None[134](index=134&type=chunk) [Other Information](index=44&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the last fiscal quarter - No directors or officers adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the last fiscal quarter[137](index=137&type=chunk) [Exhibits](index=44&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including agreements, notes, lease amendments, and officer certifications